THE DEAL, AT A GLANCE
From the announcementPassage Bio
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedPassage Bio raised $100M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersPassage Bio's $100M Growth Round is tied to advancing gene therapy for rare neurological diseases, with PBGM01 for GM1 gangliosidosis as the stated capital focus.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Passage Bio · Financing Record
Explore source-linked visual explanations for Passage Bio. Unsupported claims are withheld while source review continues.
Record 945 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →